{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:39:49Z","timestamp":1740173989436,"version":"3.37.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T00:00:00Z","timestamp":1506470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T00:00:00Z","timestamp":1506470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40744-017-0083-1","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T11:48:42Z","timestamp":1506512922000},"page":"427-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective"],"prefix":"10.1007","volume":"4","author":[{"given":"Rebekah H.","family":"Borse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Muszbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ashraf","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,27]]},"reference":[{"key":"83_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","volume":"48","author":"D Elewaut","year":"2009","unstructured":"Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 2009;48:1029\u201335.","journal-title":"Rheumatology (Oxford)"},{"key":"83_CR2","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.2004.029728","volume":"64","author":"A Wanders","year":"2005","unstructured":"Wanders A, Landew\u00e9 R, Dougados M, et al. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis. 2005;64:988\u201394.","journal-title":"Ann Rheum Dis"},{"key":"83_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"83_CR4","unstructured":"NHS Choices. Ankylosing spondylitis 2014. http:\/\/www.nhs.uk\/conditions\/Ankylosing-spondylitis\/Pages\/Introduction.aspx."},{"key":"83_CR5","unstructured":"National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. 2016. https:\/\/www.nice.org.uk\/guidance\/ta383\/resources\/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis-82602848027077."},{"key":"83_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/rheumatology\/kem296","volume":"47","author":"RM Ara","year":"2008","unstructured":"Ara RM, Packham JC, Haywood KL. The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. Rheumatology (Oxford). 2008;47:68\u201371.","journal-title":"Rheumatology (Oxford)"},{"key":"83_CR7","first-page":"289","volume":"33","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol. 2006;33:289\u201395.","journal-title":"J Rheumatol"},{"key":"83_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00252.x","volume":"11","author":"G Kobelt","year":"2008","unstructured":"Kobelt G, Sobocki P, Mulero J, et al. The burden of ankylosing spondylitis in Spain. Value Health. 2008;11:408\u201315.","journal-title":"Value Health"},{"key":"83_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3899\/jrheum.150540","volume":"43","author":"JD Greenberg","year":"2016","unstructured":"Greenberg JD, Palmer JB, Li Y, et al. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J Rheumatol. 2016;43:88\u201396.","journal-title":"J Rheumatol"},{"key":"83_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#","volume":"46","author":"MM Ward","year":"2002","unstructured":"Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. 2002;46:223\u201331.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"83_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(9):333.","journal-title":"Health Technol Assess"},{"key":"83_CR12","unstructured":"National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 233: Golimumab for the treatment of ankylosing spondylitis. 2012. https:\/\/www.nice.org.uk\/guidance\/ta233."},{"key":"83_CR13","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402\u201312.","journal-title":"Arthritis Rheum"},{"key":"83_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/ard.2011.154799","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4\u00a0weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71:661\u20137.","journal-title":"Ann Rheum Dis"},{"key":"83_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11280","volume":"11","author":"C McLeod","year":"2007","unstructured":"McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1\u2013158.","journal-title":"Health Technol Assess"},{"key":"83_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/rheumatology\/keg107","volume":"42","author":"G Kobelt","year":"2003","unstructured":"Kobelt G, J\u00f6nsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology. 2003;42:326\u201335.","journal-title":"Rheumatology"},{"key":"83_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/11314690-000000000-00000","volume":"28","author":"JP Jansen","year":"2010","unstructured":"Jansen JP, Gaugris S, Choy EH, et al. Cost-effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics. 2010;28:323\u201344.","journal-title":"Pharmacoeconomics"},{"key":"83_CR18","doi-asserted-by":"crossref","first-page":"160326","DOI":"10.1155\/2011\/160326","volume":"2011","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Taylor SD. Cost-effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis in Norway. Int J Rheumatol. 2011;2011:160326.","journal-title":"Int J Rheumatol"},{"key":"83_CR19","unstructured":"British Society for Rheumatology (BSR). BSR Guidelines for prescribing TNF\u03b1 blockers in adults with ankylosing spondylitis. 2008. http:\/\/www.rheumatology.org.uk\/includes\/documents\/cm_docs\/2009\/p\/prescribing_tnf_alpha_blockers_in_adults_with_ankylosing_spondylitis.pdf."},{"key":"83_CR20","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3\u00a0years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7:R439\u201344.","journal-title":"Arthritis Res Ther"},{"key":"83_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"83_CR22","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667\u201375.","journal-title":"Arthritis Rheum"},{"key":"83_CR23","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230\u20136.","journal-title":"Arthritis Rheum"},{"key":"83_CR24","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349\u201356.","journal-title":"N Engl J Med"},{"key":"83_CR25","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50\u00a0mg once weekly is as effective as 25\u00a0mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:1572\u20137.","journal-title":"Ann Rheum Dis"},{"key":"83_CR26","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum"},{"key":"83_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","volume":"24","author":"AE Ades","year":"2006","unstructured":"Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006;24:1\u201319.","journal-title":"Pharmacoeconomics"},{"key":"83_CR28","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/rheumatology\/keh271","volume":"43","author":"G Kobelt","year":"2004","unstructured":"Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford). 2004;43:1158\u201366.","journal-title":"Rheumatology (Oxford)"},{"key":"83_CR29","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8\u00a0years\u2019 surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69:2002\u20138.","journal-title":"Ann Rheum Dis"},{"key":"83_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/ard.2007.075879","volume":"67","author":"J Braun","year":"2008","unstructured":"Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5\u00a0years: evidence for different types of response. Ann Rheum Dis. 2008;67:340\u20135.","journal-title":"Ann Rheum Dis"},{"key":"83_CR31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.081033","volume":"36","author":"B Dijkmans","year":"2009","unstructured":"Dijkmans B, Emery P, Hakala M, et al. Etanercept in the long-term treatment of patients with ankylosing spondylitis. J Rheumatol. 2009;36:1256\u201364.","journal-title":"J Rheumatol"},{"key":"83_CR32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/bmj.284.6314.449","volume":"284","author":"PG Smith","year":"1982","unstructured":"Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with X rays. Br Med J (Clin Res Ed). 1982;284:449\u201360.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"83_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/ard.52.3.174","volume":"52","author":"K Lehtinen","year":"1993","unstructured":"Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52:174\u20136.","journal-title":"Ann Rheum Dis"},{"key":"83_CR34","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"key":"83_CR35","unstructured":"National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"key":"83_CR36","unstructured":"National Institute for Health and Clinical Excellence (NICE). Golimumab for Ankylosing Spondylitis. 2011. https:\/\/www.nice.org.uk\/guidance\/ta233\/documents\/ankylosing-spondylitis-golimumab-merck-sharpe-and-dohme2."},{"key":"83_CR37","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Schulpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"key":"83_CR38","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281\u20135.","journal-title":"J Rheumatol"},{"key":"83_CR39","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","volume":"53","author":"C Bao","year":"2014","unstructured":"Bao C, Huang F, Khan MA, et al. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford). 2014;53:1654\u201363.","journal-title":"Rheumatology (Oxford)"},{"key":"83_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Van der Heijde","year":"2005","unstructured":"Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582\u201391.","journal-title":"Arthritis Rheum"},{"key":"83_CR41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo-Ortega","year":"2005","unstructured":"Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis. 2005;64:1568\u201375.","journal-title":"Ann Rheum Dis"},{"key":"83_CR42","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","volume":"30","author":"AR Giardina","year":"2010","unstructured":"Giardina AR, Ferrante A, Ciccia F, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30:1437\u201340.","journal-title":"Rheumatol Int"},{"key":"83_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011;70:799\u2013804.","journal-title":"Ann Rheum Dis"},{"key":"83_CR44","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594\u2013600.","journal-title":"Ann Rheum Dis"},{"key":"83_CR45","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/ard.2009.121327","volume":"69","author":"N Barkham","year":"2010","unstructured":"Barkham N, Coates LC, Keen H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis. 2010;69:1926\u20138.","journal-title":"Ann Rheum Dis"},{"key":"83_CR46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1756-185X.2012.01734.x","volume":"15","author":"Z Hu","year":"2012","unstructured":"Hu Z, Xu M, Li Q, et al. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheumat Dis. 2012;15:358\u201365.","journal-title":"Int J Rheumat Dis"},{"key":"83_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2013","unstructured":"Huang F. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheumat Dis. 2013;73:587\u201394.","journal-title":"Ann Rheumat Dis"},{"key":"83_CR48","first-page":"S217","volume":"52","author":"W Maksymowych","year":"2005","unstructured":"Maksymowych W, Rahman P, Keystone E, et al. Efficacy of adalimumab in active ankylosing spondylitis (AS)\u2014results of the Canadian AS study. Arthritis Rheum. 2005;52:S217.","journal-title":"Arthritis Rheum"},{"key":"83_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis"},{"key":"83_CR50","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/rheumatology\/kem133","volume":"46","author":"RM Ara","year":"2007","unstructured":"Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford). 2007;46:1338\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"83_CR51","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/rheumatology\/kem031","volume":"46","author":"MF Botteman","year":"2007","unstructured":"Botteman MF, Hay JW, Luo MP, et al. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford). 2007;46:1320\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"83_CR52","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1017\/S0266462307070432","volume":"23","author":"G Kobelt","year":"2007","unstructured":"Kobelt G, Sobocki P, Sieper J, et al. Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int J Technol Assess Health Care. 2007;23:368\u201375.","journal-title":"Int J Technol Assess Health Care"},{"key":"83_CR53","unstructured":"National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 143: Adalimumab, etanercept and infliximab for ankylosing spondylitis. 2008. https:\/\/www.nice.org.uk\/guidance\/ta143."},{"key":"83_CR54","doi-asserted-by":"publisher","first-page":"A467","DOI":"10.1016\/S1098-3015(11)72987-4","volume":"13","author":"N Muszbek","year":"2010","unstructured":"Muszbek N, Punekar Y, Buchanan J, et al. Cost-effectiveness of golimumab in ankylosing spondylitis from the UK payer perspective. Value Health. 2010;13:A467.","journal-title":"Value Health"},{"key":"83_CR55","doi-asserted-by":"publisher","first-page":"A311","DOI":"10.1016\/j.jval.2011.08.433","volume":"14","author":"J Farrell","year":"2011","unstructured":"Farrell J, Muszbek N, Sheppard O, et al. The long term cost-effectiveness of golimumab for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Value Health. 2011;14:A311.","journal-title":"Value Health"},{"key":"83_CR56","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40273-013-0049-2","volume":"31","author":"N Armstrong","year":"2013","unstructured":"Armstrong N, Joore M, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. 2013;31:415\u201325.","journal-title":"Pharmacoeconomics"},{"key":"83_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","volume":"17","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17:157\u201373.","journal-title":"Value Health"},{"key":"83_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rhuem Dis. 2011;70:157\u201363.","journal-title":"Ann Rhuem Dis."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-017-0083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-017-0083-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-017-0083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:10:07Z","timestamp":1724458207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-017-0083-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,27]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s40744-017-0083-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2017,9,27]]},"assertion":[{"value":"26 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}